TMX Newsfile·2026-02-14 21:17Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Inovio Pharmaceuticals, Inc. securities between October 10, 2023, and December 26, 2025, due to alleged misleading statements regarding the company's manufacturing and regulatory prospects [1][5]. Company Overview - Inovio Pharmaceuticals is described as a biotechnology company focused on the discovery, development, and commercialization of DNA medicines aimed at treating diseases, including those associated with human papillomavirus (HPV) [5]. Legal Allegations - The lawsuit claims that during the Class Period, Inovio made false and misleading statements, including: 1. Deficiencies in the manufacturing of Inovio's CELLECTRA device [5]. 2. Unlikelihood of submitting the INO-3107 Biologics License Application (BLA) to the FDA by the second half of 2024 [5]. 3. Insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review [5]. 4. Overstated regulatory and commercial prospects for INO-3107 [5]. - The lawsuit asserts that these misstatements led to investor damages when the true information became public [5]. Class Action Participation - Investors who purchased Inovio securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm directly [3][6].